Immunologic characterization suggests reduced alloimmunization in a murine model of thalassemia intermedia
Weili Bao
Laboratory of Complement Biology, New York Blood Center, New York, New York
WB and HZ contributed equally to this manuscript.Search for more papers by this authorHui Zhong
Laboratory of Complement Biology, New York Blood Center, New York, New York
WB and HZ contributed equally to this manuscript.Search for more papers by this authorCorresponding Author
Karina Yazdanbakhsh
Laboratory of Complement Biology, New York Blood Center, New York, New York
Address reprint requests to: Karina Yazdanbakhsh, PhD, Laboratory of Complement Biology, New York Blood Center, 310 E67th Street, New York, NY 10065; e-mail: [email protected].Search for more papers by this authorWeili Bao
Laboratory of Complement Biology, New York Blood Center, New York, New York
WB and HZ contributed equally to this manuscript.Search for more papers by this authorHui Zhong
Laboratory of Complement Biology, New York Blood Center, New York, New York
WB and HZ contributed equally to this manuscript.Search for more papers by this authorCorresponding Author
Karina Yazdanbakhsh
Laboratory of Complement Biology, New York Blood Center, New York, New York
Address reprint requests to: Karina Yazdanbakhsh, PhD, Laboratory of Complement Biology, New York Blood Center, 310 E67th Street, New York, NY 10065; e-mail: [email protected].Search for more papers by this authorAbstract
Background
Transfusion therapy remains a mainstay of treatment for patients with thalassemia major and to a lesser extent for the less anemic patients with thalassemia intermedia. We have previously reported a role for regulatory T cells (Tregs) in the control of antibody responses in wild-type C57BL/6 (WT) mice exposed to allogeneic red blood cell transfusions. As an initial step to study and characterize immune regulation in thalassemias, we performed an immunologic cell–type characterization of C57BL/6 Hbbth-1/Hbbth-1 mouse model of thalassemia intermedia (Thal) in steady state as well as after transfusions with allogeneic blood.
Study Design and Methods
The myeloid and lymphocyte compartments including Tregs and T helper (Th) responses were analyzed in transfusion naive Thal and WT mouse spleens. The effect of allogeneic transfusions on Treg and global T helper responses was also measured.
Results
We found elevated levels and activity of splenic Tregs in Thal mice with lower Th type 1/Th type 2 ratios before as well as after transfusion. Furthermore, pretransfused Thal mice had altered ratios of the splenic myeloid compartment with increased proportion of macrophages but lower frequency of conventional dendritic cells. Surprisingly, transfusions resulted in lower alloimmunization levels in Thal compared to WT mice.
Conclusion
These data suggest that this experimental model of thalassemia intermedia has an intrinsic alteration in splenic immunoregulation with an increased resistance to alloimmunization, raising the possibility that studying this animal model may help to identify potential immunoregulatory networks to inhibit alloimmunization.
Supporting Information
Filename | Description |
---|---|
trf12683-sup-0001-si.doc1.2 MB |
Fig. S1. Ficoll treatment of donor huGPA RBCs. Anticoagulated blood obtained from huGPA mice was layered over Histopaque-1077 (Sigma-Aldrich) under sterile conditions prior to centrifugation to remove the mononuclear, according to manufacturer's instructions. The RBC-enriched pellet was then washed several times and subjected to density gradient centrifugation using Histopaque-1119 (Sigma-Aldrich) followed in order to remove granulocytes. Representative dot plots of CD45 positive leukocytes in blood from mouse huGPA (A) before and (B) after Histopaque (“Ficoll”) treatment are shown and indicate that in treated samples, these cells are undetectable. (C) Following WBC-reduction using Ficoll, huGPA RBCs were labeled with a fluorescent linker (PKH-26, Sigma-Aldrich) and transfused into WT mice. Mice were bled shortly thereafter and analyzed by flow cytometry. Representative histogram showing the PKH-negative (recipient blood) and PKH-positive (transfused/donor) RBCs are shown, and by gating on the PKH-negative or PKH-positive populations, the forward and side-scatter dot plots of PKH-negative (recipient blood, D) and (PKH-positive, E) RBC populations are indicated and appear comparable in their relative distribution. Since the transfused RBCs (PKH-positive) represent only about 5% of total RBCs, the dot plot for PKH-negative RBCs only show about 5% of the total events so that roughly equivalent numbers of cells relative to PKH-positive RBCs are displayed. Fig. S2. Alloantibody reactivity with huGPA versus FVB RBCs. Mice (n = 12, consisting of both WT and Thal) were transfused with buffy-coat/granulocyte-depleted huGPA RBCs (Fig. S1) equivalent to 1-2 packed units with CpG-ODN adjuvant, followed by weekly transfusions of red cells alone for another 3 weeks. Since huGPA mice are on the FVB background strain, the presence of IgG-specific alloantibodies against FVB and huGPA RBCs in diluted (1 in 20) mouse plasma was measured using flow cytometry by a previously described IAT.18,19 (A) As a control, reactivity of diluted plasma from untransfused mice against RBCs from FVB and huGPA mice were tested and representative histograms show background fluorescence of those RBCs. The mean fluorescent units (MFI) are indicated for each histogram. (B) Representative histograms of FVB and huGPA RBC fluorescence showing that the transfused mouse has made a strong and specific alloantibody that is reactive with huGPA RBCs in this particular mouse. (C) Alloantibody responses against FVB and huGPA RBCs for each individual transfused mouse (#1 through #12) were expressed as MFIs and shown in the table. “Difference” is the MFI units of reactivity with huGPA RBCs subtracted from MFI units of reactivity with FVB RBCs. Table S1. List of antibodies and clones used for multi-color flow cytometry |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Weatherall DJ. Pathophysiology of thalassaemia. Baillieres Clin Haematol 1998; 11: 127-146.
- 2 Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000; 96: 3624-3629.
- 3 Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011; 118: 3479-3488.
- 4 Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115: 1886-1892.
- 5 Sirchia G, Zanella A, Parravicini A, et al. Red cell alloantibodies in thalassemia major. Results of an Italian cooperative study. Transfusion 1985; 25: 110-112.
- 6 Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000; 96: 3369-3373.
- 7 Wang LY, Liang DC, Liu HC, et al. Alloimmunization among patients with transfusion-dependent thalassemia in Taiwan. Transfus Med 2006; 16: 200-203.
- 8 Spanos T, Karageorga M, Ladis V, et al. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58: 50-55.
- 9 Pahuja S, Pujani M, Gupta SK, et al. Alloimmunization and red cell autoimmunization in multitransfused thalassemics of Indian origin. Hematology 2010; 15: 174-177.
- 10 Vichinsky E, Neumayr L, Trimble S, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention. Transfusion 2014; 54: 972-981.
- 11 Thompson AA, Cunningham MJ, Singer ST, et al. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol 2011; 153: 121-128.
- 12 Taher AT, Musallam KM, Cappellini MD, et al. Optimal management of beta thalassaemia intermedia. Br J Haematol 2011; 152: 512-523.
- 13 Zimring JC, Stowell SR, Johnsen JM, et al. Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: current paradigms and future considerations. Transfus Clin Biol 2012; 19: 125-131.
- 14 Bauer MP, Wiersum-Osselton J, Schipperus M, et al. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007; 47: 2066-2071.
- 15 Noizat-Pirenne F, Tournamille C, Bierling P, et al. Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis. Transfusion 2006; 46: 1328-1333.
- 16 Zalpuri S, Zwaginga JJ, le Cessie S, et al. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012; 102: 144-149.
- 17 Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120: 528-537.
- 18 Bao W, Yu J, Heck S, et al. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 2009; 113: 5624-5627.
- 19 Yu J, Heck S, Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol 2007; 82: 691-696.
- 20 Skow LC, Burkhart BA, Johnson FM, et al. A mouse model for beta-thalassemia. Cell 1983; 34: 1043-1052.
- 21 Auffray I, Marfatia S, De Jong K, et al. Glycophorin A dimerization and band 3 interaction during erythroid membrane biogenesis: in vivo studies in human glycophorin A transgenic mice. Blood 2001; 97: 2872-2878.
- 22 Idoyaga J, Suda N, Suda K, et al. Antibody to Langerin/CD207 localizes large numbers of CD8alpha+ dendritic cells to the marginal zone of mouse spleen. Proc Natl Acad Sci U S A 2009; 106: 1524-1529.
- 23 Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
- 24 Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8: 337-348.
- 25 Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30: 1-22.
- 26 Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007; 7: 543-555.
- 27 Reizis B, Bunin A, Ghosh HS, et al. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 2011; 29: 163-183.
- 28 Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287-296.
- 29 Spack E Jr, Edidin M. The class I MHC antigens of erythrocytes: a serologic and biochemical study. J Immunol 1986; 136: 2943-2952.
- 30 Buetens O, Shirey RS, Goble-Lee M, et al. Prevalence of HLA antibodies in transfused patients with and without red cell antibodies. Transfusion 2006; 46: 754-756.
- 31 McPherson ME, Anderson AR, Castillejo MI, et al. HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr Blood Cancer 2010; 54: 552-558.
- 32 Korn T, Oukka M, Kuchroo V, et al. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007; 19: 362-371.
- 33 Bao W, Zhong H, Li X, et al. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major. Am J Hematol 2011; 86: 1001-1006.
- 34 Bozdogan G, Erdem E, Demirel GY, et al. The role of Treg cells and FoxP3 expression in immunity of beta-thalassemia major AND beta-thalassemia trait patients. Pediatr Hematol Oncol 2010; 27: 534-545.
- 35 Szczepanek SM, McNamara JT, Secor ER Jr, et al. Splenic morphological changes are accompanied by altered baseline immunity in a mouse model of sickle-cell disease. Am J Pathol 2012; 181: 1725-1734.
- 36 Belkaid Y, Piccirillo CA, Mendez S, et al. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420: 502-507.
- 37 Porrett PM, Yuan X, Larosa DF, et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 2008; 181: 1692-1699.
- 38 Larosa DF, Gelman AE, Rahman AH, et al. CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett 2007; 108: 183-188.
- 39 Hendrickson JE, Hod EA, Perry JR, et al. Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion 2012; 52: 231-240.
- 40 Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. Blood 1990; 76: 1431-1437.
- 41 Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005; 5: 606-616.
- 42 Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010; 16: 177-182.
- 43 Bozzini CE, Barrio Rendo ME, Devoto FC, et al. Studies on medullary and extramedullary erythropoiesis in the adult mouse. Am J Physiol 1970; 219: 724-728.
- 44 Libani IV, Guy EC, Melchiori L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood 2008; 112: 875-885.
- 45 Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood 1993; 82: 374-377.
- 46 Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101.
- 47 Hendrickson JE, Saakadze N, Cadwell CM, et al. The spleen plays a central role in primary humoral alloimmunization to transfused mHEL red blood cells. Transfusion 2009; 49: 1678-1684.